Bio-Techne (TECH), What Is Behind The Latest Attention?
Bio-Techne (TECH) recently completed a share repurchase program that ran from May 2025 to June 2026, retiring 2,852,695 shares, or 1.82% of its share count, for a total of US$141.73 million.
Against this backdrop, Bio-Techne’s recent buyback comes after a period of strong share price momentum, with a 90 day share price return of 41.95% and a 1 year total shareholder return of 35.88%, although the 5 year total shareholder return is down 42.55%. Recent updates on earnings and climate targets have added to the flow of company specific news. The current US$72.18 share price reflects that investors have already reacted to these developments.
Compare Bio-Techne’s buyback and recent momentum with a curated set of resilient compounders in our 74 resilient stocks with low risk scores to see how other stocks with lower risk scores are shaping up.
After a sharp rebound in Bio-Techne’s share price and a completed buyback, the easy gains may already be in the rearview mirror. Does the current valuation still offer enough potential upside to justify taking on new risk?
Most Popular Narrative: 3.5% Overvalued
Bio-Techne's most followed valuation narrative points to a fair value of about $69.73, slightly below the recent $72.18 share price. This frames the current merger bid and recent rally in a tight valuation range.
The company's shift in portfolio focus, highlighted by the divestiture of Exosome Diagnostics, allows redeployment of capital and resources toward higher-margin core business segments and growth pillars. This supports both immediate operating margin improvement (expected 100 to 200 basis point expansion) and higher future earnings. Accelerated innovation and product launches in automated proteomic instrumentation (for example, Leo Simple Western and Maurice) and digital platforms are driving high-margin, high-throughput product adoption, increasingly embedding the company's solutions in regulated pharma manufacturing workflows.
Want to understand why this narrative still supports a rich valuation for Bio-Techne even with earnings forecasts already baked in. The entire case leans on a specific blend of revenue growth assumptions, margin expansion and a future earnings multiple that sits well above the broader life sciences tools group. Curious which of these inputs does the heavy lifting in the fair value calculation.
Result: Fair Value of $69.73 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Bio-Techne’s story could shift if biotech and academic funding weakens further, or if new tariffs and regulatory changes weigh on large pharma customer demand.
Find out about the key risks to this Bio-Techne narrative.
Next Steps
If the tone of the recent Bio-Techne narrative feels optimistic, now is the moment to review the underlying data and pressure test the assumptions for yourself. To see what is driving that optimism, start with the 2 key rewards.
Looking for more investment ideas beyond Bio-Techne?
If Bio-Techne has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to uncover fresh stock ideas that fit your style.
- Target potential mispriced opportunities by scanning for companies that combine quality fundamentals with attractive valuations through the 50 high quality undervalued stocks.
- Strengthen your income focus by reviewing higher yielding companies that appear more resilient using the 12 dividend fortresses.
- Prioritise financial resilience by filtering for companies with healthier balance sheets and solid fundamentals using the list of solid balance sheet and fundamentals (53 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com